Prexasertib lactate hydrate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562011

CAS#: 2100300-72-7 (lactate hydrate)

Description: Prexasertib, also know LY2606368, is a small molecule checkpoint kinase inhibitor that causes DNA double-strand breaks, which results in apoptosis. Prexasertib is mainly active against CHEK1, with minor activity against CHEK2. Preclinical studies have shown that prexasertib induces DNA damage and tumor cell apoptosis in monotherapy. Prexasertib may also potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents.

Chemical Structure

img
Prexasertib lactate hydrate
CAS# 2100300-72-7 (lactate hydrate)
Instruction

Theoretical Analysis

MedKoo Cat#: 562011
Name: Prexasertib lactate hydrate
CAS#: 2100300-72-7 (lactate hydrate)
Chemical Formula: C21H27N7O6
Exact Mass: 0.00
Molecular Weight: 473.490
Elemental Analysis: C, 53.27; H, 5.75; N, 20.71; O, 20.27

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 1234015-54-3 (2HCl)   1234015-55-4 (mesylate)   1234015-58-7 (2 mesylate)   1234015-52-1 (free base)   1234015-57-6 (mesylate hydrate)   2100300-72-7 (lactate hydrate)   2781996-46-9 (lactate)    

Synonym: Prexasertib monolactate monohydrate; Prexasertib monolactate monohydrate salt; LY2606368; LY-2606368; LY 2606368.

IUPAC/Chemical Name: 5-[[5-[2-(3-Aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile lactate salt monohydrate

InChi Key: SQQVRJAAUOKBIG-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H19N7O2.C3H6O3.H2O/c1-26-14-4-2-5-15(27-7-3-6-19)18(14)13-8-16(25-24-13)23-17-11-21-12(9-20)10-22-17;1-2(4)3(5)6;/h2,4-5,8,10-11H,3,6-7,19H2,1H3,(H2,22,23,24,25);2,4H,1H3,(H,5,6);1H2

SMILES Code: N#CC1=NC=C(NC2=NNC(C3=C(OC)C=CC=C3OCCCN)=C2)N=C1.OC(C)C(O)=O.[H]O[H]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 473.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Giudice E, Huang TT, Nair JR, Zurcher G, McCoy A, Nousome D, Radke MR, Swisher EM, Lipkowitz S, Ibanez K, Donohue D, Malys T, Lee MJ, Redd B, Levy E, Rastogi S, Sato N, Trepel JB, Lee JM. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial. Nat Commun. 2024 Mar 30;15(1):2805. doi: 10.1038/s41467-024-47215-6. PMID: 38555285; PMCID: PMC10981752.


2: Konstantinopoulos PA, Lee JM, Gao B, Miller R, Lee JY, Colombo N, Vergote I, Credille KM, Young SR, McNeely S, Wang XA, Lin AB, Shapira-Frommer R. A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer. Gynecol Oncol. 2022 Nov;167(2):213-225. doi: 10.1016/j.ygyno.2022.09.019. Epub 2022 Sep 30. PMID: 36192237; PMCID: PMC10673677.


3: Moore KN, Hong DS, Patel MR, Pant S, Ulahannan SV, Jones S, Meric-Bernstam F, Wang JS, Aljumaily R, Hamilton EP, Wittchen ES, Wang X, Lin AB, Bendell JC. A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Target Oncol. 2021 Sep;16(5):569-589. doi: 10.1007/s11523-021-00835-0. Epub 2021 Sep 24. PMID: 34559360.


4: Do KT, Kochupurakkal B, Kelland S, de Jonge A, Hedglin J, Powers A, Quinn N, Gannon C, Vuong L, Parmar K, Lazaro JB, D'Andrea AD, Shapiro GI. Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors. Clin Cancer Res. 2021 Sep 1;27(17):4710-4716. doi: 10.1158/1078-0432.CCR-21-1279. Epub 2021 Jun 15. PMID: 34131002.


5: Ostergaard J, Jonart LM, Ebadi M, Koppenhafer SL, Gordon DJ, Gordon PM. Preclinical efficacy of prexasertib in acute lymphoblastic leukemia. Br J Haematol. 2021 Sep;194(6):1094-1098. doi: 10.1111/bjh.17610. Epub 2021 Jun 7. PMID: 34096630; PMCID: PMC8504167.


6: Byers LA, Navarro A, Schaefer E, Johnson M, Özgüroğlu M, Han JY, Bondarenko I, Cicin I, Dragnev KH, Abel A, Wang X, McNeely S, Hynes S, Lin AB, Forster M. A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. Clin Lung Cancer. 2021 Nov;22(6):531-540. doi: 10.1016/j.cllc.2021.04.005. Epub 2021 Apr 24. PMID: 34034991.


7: Cash T, Fox E, Liu X, Minard CG, Reid JM, Scheck AC, Weigel BJ, Wetmore C. A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515). Pediatr Blood Cancer. 2021 Sep;68(9):e29065. doi: 10.1002/pbc.29065. Epub 2021 Apr 21. PMID: 33881209; PMCID: PMC9090141.


8: Liu C, Xie J, Wu W, Wang M, Chen W, Idres SB, Rong J, Deng LW, Khan SA, Wu J. Automated synthesis of prexasertib and derivatives enabled by continuous-flow solid-phase synthesis. Nat Chem. 2021 May;13(5):451-457. doi: 10.1038/s41557-021-00662-w. Epub 2021 Apr 19. PMID: 33875818; PMCID: PMC8054510.


9: Do KT, Manuszak C, Thrash E, Giobbie-Hurder A, Hu J, Kelland S, Powers A, de Jonge A, Shapiro GI, Severgnini M. Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high- grade serous ovarian cancer and other solid tumors. Cancer Immunol Immunother. 2021 Oct;70(10):2991-3000. doi: 10.1007/s00262-021-02910-x. Epub 2021 Mar 20. PMID: 33745032.


10: Yang ES, Deutsch E, Mehmet A, Fayette J, Tao Y, Nabell L, Spencer SA, Wang XA, Spoljoric EA, Zhang W, Hynes SM, Decker RL, Lin AKB, William WN Jr. A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma. Radiother Oncol. 2021 Apr;157:203-209. doi: 10.1016/j.radonc.2021.01.032. Epub 2021 Feb 9. PMID: 33577866.


11: Hong DS, Moore KN, Bendell JC, Karp DD, Wang JS, Ulahannan SV, Jones S, Wu W, Donoho GP, Ding Y, Capen A, Wang X, Bence Lin A, Patel MR. Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Clin Cancer Res. 2021 Apr 1;27(7):1864-1874. doi: 10.1158/1078-0432.CCR-20-3242. Epub 2021 Jan 25. PMID: 33495309.


12: Chaudhary R, Slebos RJC, Song F, McCleary-Sharpe KP, Masannat J, Tan AC, Wang X, Amaladas N, Wu W, Hall GE, Conejo-Garcia JR, Hernandez-Prera JC, Chung CH. Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. Mol Carcinog. 2021 Feb;60(2):138-150. doi: 10.1002/mc.23275. Epub 2020 Dec 30. PMID: 33378592; PMCID: PMC7856233.


13: Lee KJ, Wright G, Bryant H, Wiggins LA, Schuler M, Gassman NR. EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer. Cancer Drug Resist. 2020 Dec 5;3(4):980-991. doi: 10.20517/cdr.2020.73. PMID: 35582228; PMCID: PMC8992551.


14: Lampert EJ, Cimino-Mathews A, Lee JS, Nair J, Lee MJ, Yuno A, An D, Trepel JB, Ruppin E, Lee JM. Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses. J Immunother Cancer. 2020 Jul;8(2):e000516. doi: 10.1136/jitc-2019-000516. PMID: 32709712; PMCID: PMC7380948.


15: Nair J, Huang TT, Murai J, Haynes B, Steeg PS, Pommier Y, Lee JM. Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer. Oncogene. 2020 Aug;39(33):5520-5535. doi: 10.1038/s41388-020-1383-4. Epub 2020 Jul 9. PMID: 32647134; PMCID: PMC7426265.


16: Morimoto Y, Takada K, Takeuchi O, Watanabe K, Hirohara M, Hamamoto T, Masuda Y. Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2. Mol Cell Biochem. 2020 Sep;472(1-2):187-198. doi: 10.1007/s11010-020-03796-6. Epub 2020 Jun 21. PMID: 32567031.


17: Evangelisti G, Barra F, Moioli M, Sala P, Stigliani S, Gustavino C, Costantini S, Ferrero S. Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer. Expert Opin Investig Drugs. 2020 Aug;29(8):779-792. doi: 10.1080/13543784.2020.1783238. Epub 2020 Jun 25. PMID: 32539469.


18: Gatti-Mays ME, Karzai FH, Soltani SN, Zimmer A, Green JE, Lee MJ, Trepel JB, Yuno A, Lipkowitz S, Nair J, McCoy A, Lee JM. A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer. Oncologist. 2020 Dec;25(12):1013-e1824. doi: 10.1634/theoncologist.2020-0491. Epub 2020 Jun 24. PMID: 32510664; PMCID: PMC7938394.


19: Zeng L, Nikolaev A, Xing C, Della Manna DL, Yang ES. CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma. Mol Cancer Ther. 2020 Jun;19(6):1279-1288. doi: 10.1158/1535-7163.MCT-19-0946. Epub 2020 May 5. PMID: 32371584.


20: Blosser WD, Dempsey JA, McNulty AM, Rao X, Ebert PJ, Lowery CD, Iversen PW, Webster YW, Donoho GP, Gong X, Merzoug FF, Buchanan S, Boehnke K, Yu C, You XT, Beckmann RP, Wu W, McNeely SC, Lin AB, Martinez R. A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib. Oncotarget. 2020 Jan 21;11(3):216-236. doi: 10.18632/oncotarget.27400. PMID: 32076484; PMCID: PMC6980627.